Validation of King's Sarcoidosis Questionnaire in a Danish Population
Sponsor
University of Aarhus (Other)
Overall Status
Recruiting
CT.gov ID
NCT04388085
Collaborator
(none)
100
1
48
2.1
Study Details
Study Description
Brief Summary
The King's Sarcoidosis Questionnaire (KSQ) is a brief questionnaire assessing health status in patients with sarcoidosis. The KSQ was previously validated in English German and Dutch.
KSQ will be translated into Danish and validated in a Danish sarcoidosis population.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Validation of King's Sarcoidosis Questionnaire in a Danish Population
Actual Study Start Date
:
Dec 1, 2019
Anticipated Primary Completion Date
:
Nov 30, 2023
Anticipated Study Completion Date
:
Nov 30, 2023
Outcome Measures
Primary Outcome Measures
- KSQ validity in Danish [2 year]
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Diagnosed with sarcoidosis
-
Signed informed consent
Exclusion Criteria:
-
Inability or unwillingness to adhere to the study
-
Inability to give informed consent
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Aarhus University Hospital. Dep. of Respiatory Diseases and Allergology | Aarhus N | Denmark | 8200 |
Sponsors and Collaborators
- University of Aarhus
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
University of Aarhus
ClinicalTrials.gov Identifier:
NCT04388085
Other Study ID Numbers:
- SAR2
First Posted:
May 14, 2020
Last Update Posted:
Sep 29, 2021
Last Verified:
Sep 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: